The latest research study released by Market IntelliX evaluates market size and forecasts of Graft Versus Host Disease Treatment in Global, including the following market information:

Global Graft Versus Host Disease Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Graft Versus Host Disease Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Etanercept Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Graft Versus Host Disease Treatment include AbbVie Inc., Acrofan, Astellas Pharma Inc., Bristol-Myers Squibb Company, ElsaLys Biotech SA, F. Hoffmann-La Roche AG, Johnson & Johnson, Mallinckrodft PLC and Merck & Co., Inc., etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MI has surveyed the Graft Versus Host Disease Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Market Segmentations:

Global Graft Versus Host Disease Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Graft Versus Host Disease Treatment Market Segment Percentages, by Type, 2021 (%)

Etanercept

Monoclonal Antibodies

Thalidomide

Tyrosine Kinase Inhibitors

mTOR Inhibitors

Global Graft Versus Host Disease Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Graft Versus Host Disease Treatment Market Segment Percentages, by Application, 2021 (%)

Acute GVHD

Chronic GVHD

Prophylaxis GVHD

Global Graft Versus Host Disease Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Graft Versus Host Disease Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Graft Versus Host Disease Treatment revenues in global market, 2017-2022 (estimated), ($ millions)

Key companies Graft Versus Host Disease Treatment revenues share in global market, 2021 (%)

The report presents profiles of competitors in the market, Some of the prominent key players covered:

AbbVie Inc.

Acrofan

Astellas Pharma Inc.

Bristol-Myers Squibb Company

ElsaLys Biotech SA

F. Hoffmann-La Roche AG

Johnson & Johnson

Mallinckrodft PLC

Merck & Co., Inc.

Mesoblast Limited

Neovii Biotech GmbH

Novartis AG

Ocugen, Inc.

Pfizer Inc

Pluristem Therapeutics Inc.

Samedan Ltd

Sanofi SA

Soligenix, Inc.

Key Takeaways from this Report

Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level – for product types, end use applications and by different industry verticals.

Understand the different dynamics influencing the market – key driving factors, challenges and hidden opportunities.

Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.

Analyze the sales and distribution channels across key geographies to improve top-line revenues.

Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes.

Get a quick outlook on the market entropy – M&A’s, deals, partnerships, product launches of all key players for the past 4 years.

Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market.

1 Introduction to Research & Analysis Reports

1.1 Graft Versus Host Disease Treatment Market Definition

1.2 Market Segments

1.2.1 Market by Type

1.2.2 Market by Application

1.3 Global Graft Versus Host Disease Treatment Market Overview

1.4 Features & Benefits of This Report

1.5 Methodology & Sources of Information

1.5.1 Research Methodology

1.5.2 Research Process

1.5.3 Base Year

1.5.4 Report Assumptions & Caveats

2 Global Graft Versus Host Disease Treatment Overall Market Size

2.1 Global Graft Versus Host Disease Treatment Market Size: 2021 VS 2028

2.2 Global Graft Versus Host Disease Treatment Market Size, Prospects & Forecasts: 2017-2028

2.3 Key Market Trends, Opportunity, Drivers and Restraints

2.3.1 Market Opportunities & Trends

2.3.2 Market Drivers

2.3.3 Market Restraints

3 Company Landscape

3.1 Top Graft Versus Host Disease Treatment Players in Global Market

3.2 Top Global Graft Versus Host Disease Treatment Companies Ranked by Revenue

3.3 Global Graft Versus Host Disease Treatment Revenue by Companies

3.4 Top 3 and Top 5 Graft Versus Host Disease Treatment Companies in Global Market, by Revenue in 2021

3.5 Global Companies Graft Versus Host Disease Treatment Product Type

3.6 Tier 1, Tier 2 and Tier 3 Graft Versus Host Disease Treatment Players in Global Market

3.6.1 List of Global Tier 1 Graft Versus Host Disease Treatment Companies

3.6.2 List of Global Tier 2 and Tier 3 Graft Versus Host Disease Treatment Companies

4 Market Sights by Product

4.1 Overview

4.1.1 by Type - Global Graft Versus Host Disease Treatment Market Size Markets, 2021 & 2028

4.1.2 Etanercept

4.1.3 Monoclonal Antibodies

4.1.4 Thalidomide

4.1.5 Tyrosine Kinase Inhibitors

4.1.6 mTOR Inhibitors

4.2 By Type - Global Graft Versus Host Disease Treatment Revenue & Forecasts

4.2.1 By Type - Global Graft Versus Host Disease Treatment Revenue, 2017-2022

4.2.2 By Type - Global Graft Versus Host Disease Treatment Revenue, 2023-2028

4.2.3 By Type - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

5 Sights by Application

5.1 Overview

5.1.1 By Application - Global Graft Versus Host Disease Treatment Market Size, 2021 & 2028

5.1.2 Acute GVHD

5.1.3 Chronic GVHD

5.1.4 Prophylaxis GVHD

5.2 By Application - Global Graft Versus Host Disease Treatment Revenue & Forecasts

5.2.1 By Application - Global Graft Versus Host Disease Treatment Revenue, 2017-2022

5.2.2 By Application - Global Graft Versus Host Disease Treatment Revenue, 2023-2028

5.2.3 By Application - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

6 Sights by Region

6.1 By Region - Global Graft Versus Host Disease Treatment Market Size, 2021 & 2028

6.2 By Region - Global Graft Versus Host Disease Treatment Revenue & Forecasts

6.2.1 By Region - Global Graft Versus Host Disease Treatment Revenue, 2017-2022

6.2.2 By Region - Global Graft Versus Host Disease Treatment Revenue, 2023-2028

6.2.3 By Region - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Graft Versus Host Disease Treatment Revenue, 2017-2028

6.3.2 US Graft Versus Host Disease Treatment Market Size, 2017-2028

6.3.3 Canada Graft Versus Host Disease Treatment Market Size, 2017-2028

6.3.4 Mexico Graft Versus Host Disease Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Graft Versus Host Disease Treatment Revenue, 2017-2028

6.4.2 Germany Graft Versus Host Disease Treatment Market Size, 2017-2028

6.4.3 France Graft Versus Host Disease Treatment Market Size, 2017-2028

6.4.4 U.K. Graft Versus Host Disease Treatment Market Size, 2017-2028

6.4.5 Italy Graft Versus Host Disease Treatment Market Size, 2017-2028

6.4.6 Russia Graft Versus Host Disease Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Graft Versus Host Disease Treatment Market Size, 2017-2028

6.4.8 Benelux Graft Versus Host Disease Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Graft Versus Host Disease Treatment Revenue, 2017-2028

6.5.2 China Graft Versus Host Disease Treatment Market Size, 2017-2028

6.5.3 Japan Graft Versus Host Disease Treatment Market Size, 2017-2028

6.5.4 South Korea Graft Versus Host Disease Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Graft Versus Host Disease Treatment Market Size, 2017-2028

6.5.6 India Graft Versus Host Disease Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Graft Versus Host Disease Treatment Revenue, 2017-2028

6.6.2 Brazil Graft Versus Host Disease Treatment Market Size, 2017-2028

6.6.3 Argentina Graft Versus Host Disease Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Graft Versus Host Disease Treatment Revenue, 2017-2028

6.7.2 Turkey Graft Versus Host Disease Treatment Market Size, 2017-2028

6.7.3 Israel Graft Versus Host Disease Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Graft Versus Host Disease Treatment Market Size, 2017-2028

6.7.5 UAE Graft Versus Host Disease Treatment Market Size, 2017-2028

7 Players Profiles

7.1 AbbVie Inc.

7.1.1 AbbVie Inc. Corporate Summary

7.1.2 AbbVie Inc. Business Overview

7.1.3 AbbVie Inc. Graft Versus Host Disease Treatment Major Product Offerings

7.1.4 AbbVie Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.1.5 AbbVie Inc. Key News

7.2 Acrofan

7.2.1 Acrofan Corporate Summary

7.2.2 Acrofan Business Overview

7.2.3 Acrofan Graft Versus Host Disease Treatment Major Product Offerings

7.2.4 Acrofan Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.2.5 Acrofan Key News

7.3 Astellas Pharma Inc.

7.3.1 Astellas Pharma Inc. Corporate Summary

7.3.2 Astellas Pharma Inc. Business Overview

7.3.3 Astellas Pharma Inc. Graft Versus Host Disease Treatment Major Product Offerings

7.3.4 Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.3.5 Astellas Pharma Inc. Key News

7.4 Bristol-Myers Squibb Company

7.4.1 Bristol-Myers Squibb Company Corporate Summary

7.4.2 Bristol-Myers Squibb Company Business Overview

7.4.3 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Major Product Offerings

7.4.4 Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.4.5 Bristol-Myers Squibb Company Key News

7.5 ElsaLys Biotech SA

7.5.1 ElsaLys Biotech SA Corporate Summary

7.5.2 ElsaLys Biotech SA Business Overview

7.5.3 ElsaLys Biotech SA Graft Versus Host Disease Treatment Major Product Offerings

7.5.4 ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.5.5 ElsaLys Biotech SA Key News

7.6 F. Hoffmann-La Roche AG

7.6.1 F. Hoffmann-La Roche AG Corporate Summary

7.6.2 F. Hoffmann-La Roche AG Business Overview

7.6.3 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Major Product Offerings

7.6.4 F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.6.5 F. Hoffmann-La Roche AG Key News

7.7 Johnson & Johnson

7.7.1 Johnson & Johnson Corporate Summary

7.7.2 Johnson & Johnson Business Overview

7.7.3 Johnson & Johnson Graft Versus Host Disease Treatment Major Product Offerings

7.7.4 Johnson & Johnson Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.7.5 Johnson & Johnson Key News

7.8 Mallinckrodft PLC

7.8.1 Mallinckrodft PLC Corporate Summary

7.8.2 Mallinckrodft PLC Business Overview

7.8.3 Mallinckrodft PLC Graft Versus Host Disease Treatment Major Product Offerings

7.8.4 Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.8.5 Mallinckrodft PLC Key News

7.9 Merck & Co., Inc.

7.9.1 Merck & Co., Inc. Corporate Summary

7.9.2 Merck & Co., Inc. Business Overview

7.9.3 Merck & Co., Inc. Graft Versus Host Disease Treatment Major Product Offerings

7.9.4 Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.9.5 Merck & Co., Inc. Key News

7.10 Mesoblast Limited

7.10.1 Mesoblast Limited Corporate Summary

7.10.2 Mesoblast Limited Business Overview

7.10.3 Mesoblast Limited Graft Versus Host Disease Treatment Major Product Offerings

7.10.4 Mesoblast Limited Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.10.5 Mesoblast Limited Key News

7.11 Neovii Biotech GmbH

7.11.1 Neovii Biotech GmbH Corporate Summary

7.11.2 Neovii Biotech GmbH Business Overview

7.11.3 Neovii Biotech GmbH Graft Versus Host Disease Treatment Major Product Offerings

7.11.4 Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.11.5 Neovii Biotech GmbH Key News

7.12 Novartis AG

7.12.1 Novartis AG Corporate Summary

7.12.2 Novartis AG Business Overview

7.12.3 Novartis AG Graft Versus Host Disease Treatment Major Product Offerings

7.12.4 Novartis AG Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.12.5 Novartis AG Key News

7.13 Ocugen, Inc.

7.13.1 Ocugen, Inc. Corporate Summary

7.13.2 Ocugen, Inc. Business Overview

7.13.3 Ocugen, Inc. Graft Versus Host Disease Treatment Major Product Offerings

7.13.4 Ocugen, Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.13.5 Ocugen, Inc. Key News

7.14 Pfizer Inc

7.14.1 Pfizer Inc Corporate Summary

7.14.2 Pfizer Inc Business Overview

7.14.3 Pfizer Inc Graft Versus Host Disease Treatment Major Product Offerings

7.14.4 Pfizer Inc Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.14.5 Pfizer Inc Key News

7.15 Pluristem Therapeutics Inc.

7.15.1 Pluristem Therapeutics Inc. Corporate Summary

7.15.2 Pluristem Therapeutics Inc. Business Overview

7.15.3 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Major Product Offerings

7.15.4 Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.15.5 Pluristem Therapeutics Inc. Key News

7.16 Samedan Ltd

7.16.1 Samedan Ltd Corporate Summary

7.16.2 Samedan Ltd Business Overview

7.16.3 Samedan Ltd Graft Versus Host Disease Treatment Major Product Offerings

7.16.4 Samedan Ltd Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.16.5 Samedan Ltd Key News

7.17 Sanofi SA

7.17.1 Sanofi SA Corporate Summary

7.17.2 Sanofi SA Business Overview

7.17.3 Sanofi SA Graft Versus Host Disease Treatment Major Product Offerings

7.17.4 Sanofi SA Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.17.5 Sanofi SA Key News

7.18 Soligenix, Inc.

7.18.1 Soligenix, Inc. Corporate Summary

7.18.2 Soligenix, Inc. Business Overview

7.18.3 Soligenix, Inc. Graft Versus Host Disease Treatment Major Product Offerings

7.18.4 Soligenix, Inc. Graft Versus Host Disease Treatment Revenue in Global Market (2017-2022)

7.18.5 Soligenix, Inc. Key News

8 Conclusion

9 Appendix

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List of Tables

Table 1. Graft Versus Host Disease Treatment Market Opportunities & Trends in Global Market

Table 2. Graft Versus Host Disease Treatment Market Drivers in Global Market

Table 3. Graft Versus Host Disease Treatment Market Restraints in Global Market

Table 4. Key Players of Graft Versus Host Disease Treatment in Global Market

Table 5. Top Graft Versus Host Disease Treatment Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Graft Versus Host Disease Treatment Revenue by Companies, (US$, Mn), 2017-2022

Table 7. Global Graft Versus Host Disease Treatment Revenue Share by Companies, 2017-2022

Table 8. Global Companies Graft Versus Host Disease Treatment Product Type

Table 9. List of Global Tier 1 Graft Versus Host Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Graft Versus Host Disease Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share

Table 11. By Type – Global Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2021 & 2028

Table 12. By Type - Graft Versus Host Disease Treatment Revenue in Global (US$, Mn), 2017-2022

Table 13. By Type - Graft Versus Host Disease Treatment Revenue in Global (US$, Mn), 2023-2028

Table 14. By Application – Global Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2021 & 2028

Table 15. By Application - Graft Versus Host Disease Treatment Revenue in Global (US$, Mn), 2017-2022

Table 16. By Application - Graft Versus Host Disease Treatment Revenue in Global (US$, Mn), 2023-2028

Table 17. By Region – Global Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2021 & 2028

Table 18. By Region - Global Graft Versus Host Disease Treatment Revenue (US$, Mn), 2017-2022

Table 19. By Region - Global Graft Versus Host Disease Treatment Revenue (US$, Mn), 2023-2028

Table 20. By Country - North America Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022

Table 21. By Country - North America Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028

Table 22. By Country - Europe Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022

Table 23. By Country - Europe Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028

Table 24. By Region - Asia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022

Table 25. By Region - Asia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028

Table 26. By Country - South America Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022

Table 27. By Country - South America Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2023-2028

Table 30. AbbVie Inc. Corporate Summary

Table 31. AbbVie Inc. Graft Versus Host Disease Treatment Product Offerings

Table 32. AbbVie Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 33. Acrofan Corporate Summary

Table 34. Acrofan Graft Versus Host Disease Treatment Product Offerings

Table 35. Acrofan Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 36. Astellas Pharma Inc. Corporate Summary

Table 37. Astellas Pharma Inc. Graft Versus Host Disease Treatment Product Offerings

Table 38. Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 39. Bristol-Myers Squibb Company Corporate Summary

Table 40. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Product Offerings

Table 41. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 42. ElsaLys Biotech SA Corporate Summary

Table 43. ElsaLys Biotech SA Graft Versus Host Disease Treatment Product Offerings

Table 44. ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 45. F. Hoffmann-La Roche AG Corporate Summary

Table 46. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Product Offerings

Table 47. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 48. Johnson & Johnson Corporate Summary

Table 49. Johnson & Johnson Graft Versus Host Disease Treatment Product Offerings

Table 50. Johnson & Johnson Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 51. Mallinckrodft PLC Corporate Summary

Table 52. Mallinckrodft PLC Graft Versus Host Disease Treatment Product Offerings

Table 53. Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 54. Merck & Co., Inc. Corporate Summary

Table 55. Merck & Co., Inc. Graft Versus Host Disease Treatment Product Offerings

Table 56. Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 57. Mesoblast Limited Corporate Summary

Table 58. Mesoblast Limited Graft Versus Host Disease Treatment Product Offerings

Table 59. Mesoblast Limited Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 60. Neovii Biotech GmbH Corporate Summary

Table 61. Neovii Biotech GmbH Graft Versus Host Disease Treatment Product Offerings

Table 62. Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 63. Novartis AG Corporate Summary

Table 64. Novartis AG Graft Versus Host Disease Treatment Product Offerings

Table 65. Novartis AG Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 66. Ocugen, Inc. Corporate Summary

Table 67. Ocugen, Inc. Graft Versus Host Disease Treatment Product Offerings

Table 68. Ocugen, Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 69. Pfizer Inc Corporate Summary

Table 70. Pfizer Inc Graft Versus Host Disease Treatment Product Offerings

Table 71. Pfizer Inc Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 72. Pluristem Therapeutics Inc. Corporate Summary

Table 73. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Product Offerings

Table 74. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 75. Samedan Ltd Corporate Summary

Table 76. Samedan Ltd Graft Versus Host Disease Treatment Product Offerings

Table 77. Samedan Ltd Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 78. Sanofi SA Corporate Summary

Table 79. Sanofi SA Graft Versus Host Disease Treatment Product Offerings

Table 80. Sanofi SA Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

Table 81. Soligenix, Inc. Corporate Summary

Table 82. Soligenix, Inc. Graft Versus Host Disease Treatment Product Offerings

Table 83. Soligenix, Inc. Graft Versus Host Disease Treatment Revenue (US$, Mn), (2017-2022)

List of Figures

Figure 1. Graft Versus Host Disease Treatment Segment by Type in 2021

Figure 2. Graft Versus Host Disease Treatment Segment by Application in 2021

Figure 3. Global Graft Versus Host Disease Treatment Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Graft Versus Host Disease Treatment Market Size: 2021 VS 2028 (US$, Mn)

Figure 6. Global Graft Versus Host Disease Treatment Revenue, 2017-2028 (US$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Graft Versus Host Disease Treatment Revenue in 2021

Figure 8. By Type - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

Figure 9. By Application - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

Figure 10. By Region - Global Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

Figure 11. By Country - North America Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

Figure 12. US Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 13. Canada Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 14. Mexico Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 15. By Country - Europe Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

Figure 16. Germany Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 17. France Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 18. U.K. Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 19. Italy Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 20. Russia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 21. Nordic Countries Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 22. Benelux Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 23. By Region - Asia Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

Figure 24. China Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 25. Japan Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 26. South Korea Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 27. Southeast Asia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 28. India Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 29. By Country - South America Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 31. Argentina Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Graft Versus Host Disease Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 34. Israel Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 35. Saudi Arabia Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 36. UAE Graft Versus Host Disease Treatment Revenue, (US$, Mn), 2017-2028

Figure 37. AbbVie Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 38. Acrofan Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 39. Astellas Pharma Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 40. Bristol-Myers Squibb Company Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 41. ElsaLys Biotech SA Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 42. F. Hoffmann-La Roche AG Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 43. Johnson & Johnson Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 44. Mallinckrodft PLC Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 45. Merck & Co., Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 46. Mesoblast Limited Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 47. Neovii Biotech GmbH Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 48. Novartis AG Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 49. Ocugen, Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 50. Pfizer Inc Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 51. Pluristem Therapeutics Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 52. Samedan Ltd Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 53. Sanofi SA Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Figure 54. Soligenix, Inc. Graft Versus Host Disease Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)

Methodology/Research Approach

This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.

Research Programs/Design

Historical Data (2015-2019)	Industry Trends Competitive Landscape By Company Expansion Mergers and Acquisitions Market Segment by Type by Application By Regions/ Geography	Value Status and Outlook Value for Major Players Market Share Growth Rate Present Situation Analysis Value Market Share Growth Rate Present Situation Analysis
Influencing Factors	Market Environment Government Policy Technological Changes Market Risks	Market Drivers Growing Demand of Downstream Reduction in Cost
Market Forecast (2021-2026)	Overall Size by Type by Application By Regions/Geography	Key Data (Value) Market Share Growth Rate CAGR (2021-2026)

Market Size Estimation

Top-down and bottom-up approaches are used to validate the global Voluntary Carbon Offset market size market and estimate the market size for Company, regions segments, product segments and Application (end users).

The market estimations in this report are based on the marketed sale price of Voluntary Carbon Offset (excluding any discounts provided by the player, distributor, wholesaler or traders). The percentage splits, market share, and breakdowns of the product segments are derived on the basis of weights assigned to each of the segments on the basis of their utilization rate and average sale price. The regional splits of the overall Voluntary Carbon Offset market and its sub-segments are based on the percentage adoption or utilization of the given product in the respective region or country.

Major Company in the market is identified through secondary research and their market revenues determined through primary and secondary research. Secondary research included the research of the annual and financial reports of the top Company; whereas, primary research included extensive interviews of key opinion leaders and industry experts such as experienced front-line staff, directors, CEOs and marketing executives. The percentage splits, market share, Growth Rate and breakdowns of the product markets are determined through using secondary sources and verified through the primary sources.

All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Market Intellix and presented in this report

The following figure shows an illustrative representation of the overall market size estimation process used for this study.

Market Breakdown and Data Triangulation

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Data Source

Secondary Sources

Secondary sources include such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, etc. This research study involves the usage of widespread secondary sources, directories, databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), and TRADING ECONOMICS, and News Network, statista, Federal Reserve Economic Data, annual reports, BIS Statistics, ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and Hospitals study of the Voluntary Carbon Offset market. It was also used to obtain important information about the top companies, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.

Market Size	Segmental value Geographic Penetration Product Adoption Rate for Different market	Journals, Websites, and Press Releases Annual Reports and SEC Filings Company Websites and Press Releases Public and Paid Databases Market Intellix Data Repository
Market Position of Top Company	Product Financials Geographic value Mix Total Company value Business/Segmental value Mix
Qualitative Analysis	Influence Factors Market Potential Market Risks and Opportunities Industry Trends Geographical Features Government Policies	Company Websites and Press Releases Public and Paid Databases Annual Reports Industry Associations Market Intellix Data Repository

Primary Sources

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product Company (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end use (product buyers), and related key executives from various key companies and organizations operating in the global market.

Primary research was conducted to identify segmentation Type, product price range, product Application, key Company, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.

Key Executives Interviewed

Key Data Information from Primary Sources

Primary Sources	Parameters	Key Data
Market Segments(by Application, by Type)	Value by Type Status and Forecast Value by Application Value by Regions, Status and Forecast (2021-2026)	Value Market Share by Type Value Growth Rate by Type Value by Application Percentage and Growth Rate by Application Value Growth Rate and Market Share by Regions Market Size Status and Forecast (2021-2026)
Total Market	Overall Size, Status and Forecast	Market Size Status and Forecast (2021-2026)